The predictive value of MiR-221 in cancer chemoresistance: a systematic review and meta-analysis

BACKGROUND Many studies have reported that microRNA-221 (miR-221) is abnormally expressed in various cancers, and there has not been a study to systematically analyze the association between miR-221 and chemoresistance in different cancers. METHODS We systematically searched PubMed, Web of Science, Ovid, and Cochrane for relevant studies. The pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were used to estimate. RESULTS A total of 30 studies with 1670 patients were enrolled in our study. Thirteen cancer types have been studied, and traditional chemotherapy, targeted drugs, endocrine therapy, chemoradiotherapy, and other treatments were used. High miR-221 expression was associated with poor chemotherapy response in most studies, and the meta-analysis confirmed this result (OR = 3.64, 95%CI: 1.73-7.62, p = 0.001). Besides, the higher level of miR-221 was related to shorter overall survival (OS) (HR = 2.16, 95%CI: 1.47-3.16, p < 0.001) and progression-free survival (PFS) (HR = 1.81, 95%CI: 1.51-2.16, p < 0.001) in patients after chemotherapy. CONCLUSION Our results highlight that high miR-221 expression has possible associations with chemoresistance and poor prognosis in multiple cancers. Further studies are needed to discover the molecular mechanisms underlying these associations to provide a solid evidence base for it being used as biomarkers of response to chemotherapeutic interventions in cancer.

[1]  I. Clark,et al.  MicroRNA-Based Diagnosis and Therapy , 2022, International journal of molecular sciences.

[2]  Jiali Yang,et al.  Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer , 2022, Molecular cancer.

[3]  P. Tassone,et al.  miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review , 2022, Molecular therapy. Nucleic acids.

[4]  Nani Harlina Md Latar,et al.  microRNA-221 and tamoxifen resistance in luminal-subtype breast cancer patients: A case-control study , 2021, Annals of medicine and surgery.

[5]  Chia-Hung Chen,et al.  miR‐221 confers lapatinib resistance by negatively regulating p27kip1 in HER2‐positive breast cancer , 2021, Cancer science.

[6]  Zun Wang,et al.  miR-221/222 sponge abrogates tamoxifen resistance in ER-positive breast cancer cells through restoring the expression of ERα , 2021, Molecular Biomedicine.

[7]  J. Zucman‐Rossi,et al.  MicroRNAs Targeting HIF-2α, VEGFR1 and/or VEGFR2 as Potential Predictive Biomarkers for VEGFR Tyrosine Kinase and HIF-2α Inhibitors in Metastatic Clear-Cell Renal Cell Carcinoma , 2021, Cancers.

[8]  Shenglan Yang,et al.  EMT‐associated microRNAs and their roles in cancer stemness and drug resistance , 2021, Cancer communications.

[9]  S. Dawson,et al.  Non-genetic mechanisms of therapeutic resistance in cancer , 2020, Nature Reviews Cancer.

[10]  M. Swellam,et al.  Emerging role of miRNAs as liquid biopsy markers for prediction of glioblastoma multiforme prognosis , 2020, Journal of molecular neuroscience : MN.

[11]  Yusong Zhang,et al.  MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo. , 2020, European journal of pharmacology.

[12]  Le Jin,et al.  The lncRNA-GAS5/miR-221-3p/DKK2 Axis Modulates ABCB1-Mediated Adriamycin Resistance of Breast Cancer via the Wnt/β-Catenin Signaling Pathway , 2020, Molecular therapy. Nucleic acids.

[13]  B. Schilling,et al.  miR-221 Augments TRAIL-Mediated Apoptosis in Prostate Cancer Cells by Inducing Endogenous TRAIL Expression and Targeting the Functional Repressors SOCS3 and PIK3R1 , 2019, BioMed research international.

[14]  Zhiyu Wang,et al.  Long non-coding RNA TUG1 enhances chemosensitivity in non-small cell lung cancer by impairing microRNA-221-dependent PTEN inhibition , 2019, Aging.

[15]  Lining Wang,et al.  Prognostic value of miR-221 in human malignancy: evidence from 3041 subjects , 2019, BMC Cancer.

[16]  Lingfeng He,et al.  MicroRNA-140 impedes DNA repair by targeting FEN1 and enhances chemotherapeutic response in breast cancer , 2019, Oncogene.

[17]  C. Thorns,et al.  MicroRNAs as Potential Biomarkers for Chemoresistance in Adenocarcinomas of the Esophagogastric Junction , 2019, Journal of oncology.

[18]  P. Meldgaard,et al.  Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients. , 2019, Lung cancer.

[19]  P. Hrelia,et al.  Prognostic Role of miR-221 and miR-222 Expression in Cancer Patients: A Systematic Review and Meta-Analysis , 2019, Cancers.

[20]  Hui Chen,et al.  MicroRNA-221 promotes cisplatin resistance in osteosarcoma cells by targeting PPP2R2A , 2019, Bioscience reports.

[21]  Lei Chen,et al.  miR-221/222-Mediated Inhibition of Autophagy Promotes Dexamethasone Resistance in Multiple Myeloma. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  B. Shao,et al.  Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer , 2019, Technology in cancer research & treatment.

[23]  Yanhong Cheng,et al.  MicroRNA-221 sensitizes chronic myeloid leukemia cells to imatinib by targeting STAT5 , 2018, Leukemia & lymphoma.

[24]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[25]  N. Nonomura,et al.  Role of Androgen Receptor in Prostate Cancer: A Review , 2018, The world journal of men's health.

[26]  M. Gong,et al.  MiRNA-221 from tissue may predict the prognosis of patients with osteosarcoma , 2018, Medicine.

[27]  A. Huang,et al.  miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway , 2018, Journal of Hematology & Oncology.

[28]  A. Poprach,et al.  Candidate MicroRNA Biomarkers of Therapeutic Response to Sunitinib in Metastatic Renal Cell Carcinoma: A Validation Study in Patients with Extremely Good and Poor Response. , 2018, Anticancer research.

[29]  Feiran Wang,et al.  miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker , 2018, International journal of nanomedicine.

[30]  S. Wiemann,et al.  MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells , 2017, Cell Death & Disease.

[31]  Juan Shi,et al.  Combination of AAV-TRAIL with miR-221-Zip Therapeutic Strategy Overcomes the Resistance to TRAIL Induced Apoptosis in Liver Cancer , 2017, Theranostics.

[32]  P. Meltzer,et al.  Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106a in osteosarcoma. , 2017, Oncotarget.

[33]  C. Fan,et al.  Potential Value of miR-221/222 as Diagnostic, Prognostic, and Therapeutic Biomarkers for Diseases , 2017, Front. Immunol..

[34]  J. H. Kim,et al.  An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma , 2016, Journal of Korean medical science.

[35]  D. Pisano,et al.  Deep sequencing reveals microRNAs predictive of antiangiogenic drug response. , 2016, JCI insight.

[36]  G. Yousef,et al.  miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  Hongliang Liu,et al.  Serum microRNA-221 functions as a potential diagnostic and prognostic marker for patients with osteosarcoma. , 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[38]  N. Seki,et al.  MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker , 2015, British Journal of Cancer.

[39]  M. Odenthal,et al.  Serum microRNA profiles as prognostic or predictive markers in the multimodality treatment of patients with gastric cancer. , 2015, Oncology letters.

[40]  A. Fernández-Medarde,et al.  Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[41]  R. Stahel,et al.  Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). , 2014, Lung cancer.

[42]  S. Lawler,et al.  MicroRNAs in cancer: biomarkers, functions and therapy. , 2014, Trends in molecular medicine.

[43]  Q. Meng,et al.  Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3 , 2014, Cancer Gene Therapy.

[44]  R. Medeiros,et al.  Influence of peripheral whole-blood microRNA-7 and microRNA-221 high expression levels on the acquisition of castration-resistant prostate cancer: evidences from in vitro and in vivo studies , 2014, Tumor Biology.

[45]  E. Rego,et al.  Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia , 2013, Experimental Hematology & Oncology.

[46]  C. Xiao,et al.  MicroRNA-221 Induces Cell Survival and Cisplatin Resistance through PI3K/Akt Pathway in Human Osteosarcoma , 2013, PloS one.

[47]  P. Kantoff,et al.  The altered expression of MiR‐221/‐222 and MiR‐23b/‐27b is associated with the development of human castration resistant prostate cancer , 2012, The Prostate.

[48]  M. Tewari,et al.  MicroRNA profiling: approaches and considerations , 2012, Nature Reviews Genetics.

[49]  C. Croce,et al.  MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review , 2012, EMBO molecular medicine.

[50]  F. Yu,et al.  Plasma miR-221 as a Predictive Biomarker for Chemoresistance in Breast Cancer Patients who Previously Received Neoadjuvant Chemotherapy , 2011, Oncology Research and Treatment.

[51]  Chengcheng Guo,et al.  Diagnostic and Prognostic Value of Circulating miR-221 for Extranodal Natural Killer/T-Cell Lymphoma , 2011, Disease markers.

[52]  G. Berchem,et al.  Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia , 2010, Molecular Cancer.

[53]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[54]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[55]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[56]  C. Croce,et al.  MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer , 2008, Oncogene.

[57]  E. Labourier,et al.  Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues. , 2008, The Journal of molecular diagnostics : JMD.

[58]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[59]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[60]  I. Brown,et al.  Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells , 2004, Breast Cancer Research.

[61]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[62]  Soonhag Kim,et al.  Theragnosis-based combined cancer therapy using doxorubicin-conjugated microRNA-221 molecular beacon. , 2016, Biomaterials.

[63]  Feng Wang,et al.  Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma , 2016, Journal of Neuro-Oncology.

[64]  C. Croce,et al.  MicroRNAs in cancer. , 2014, Annual review of pathology.

[65]  C. Croce,et al.  miR221/222 in cancer: their role in tumor progression and response to therapy. , 2012, Current molecular medicine.

[66]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.